Sarepta rockets 20% higher after 'powerhouse' biotech tops revenue expectations
July 20, 2017 at 09:30 AM EDT
Wall Street believes the biopharma's focus on developing treatments for rare neuromuscular diseases is paying off.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.